Tharun Bandarupalli
Greenville, NCNPI 1720601289
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Medtronic at 30.3% of the total. 2025 is the largest year on record at $16,500, more than ten times the $260 reported in 2023.
Across 211 payments — averaging $111.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Biotronik Inc.$4K
- Abbott$4K
- Biosense Webster, Inc.$3K
- Boston Scientific$2K
- Abiomed$1K
- plus $2K from 14 others
What the payments were for
- Travel & lodging$13,35757%
- Food & beverage$9,81342%
- Education$4432%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 57 | $7,160 |
| Biotronik Inc. | 41 | $4,301 |
| Abbott | 35 | $4,203 |
| Biosense Webster, Inc. | 23 | $2,656 |
| Boston Scientific | 10 | $2,202 |
| Abiomed | 14 | $1,297 |
| Amgen | 8 | $308 |
| Bayer | 4 | $183 |
| Atricure, Inc. | 1 | $164 |
| Baxter Healthcare | 1 | $149 |
| Bridgebio Pharma, Inc. | 1 | $148 |
| Novartis | 6 | $144 |
| Shockwave Medical, Inc | 1 | $135 |
| Novo Nordisk | 2 | $134 |
| AstraZeneca | 1 | $125 |
| Merck | 1 | $91 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $66 |
| Terumo Medical Corporation | 1 | $64 |
| Angiodynamics, Inc. | 1 | $60 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALLANT$2,663
- Carto 3$2,052
- INGEVITY MRI$1,076
- Farapulse$742
- Acticor 7 VR-T DX$366
- PAMIRA$366
- Impella$269
- ENSITE$256
- Micra$190
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$164
- Hillrom - Cardiac Ambulatory Monitor$149
- SYMPLICITY G3$148
- Selectra$148
- Attruby$148
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$135
- AFFERA MAPPING SYSTEM$135
- Kerendia$133
- OPTIS$132
- BioMonitor$128
- Rotablator Rotational Atherectomy System Console Kit$125
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $30,895 |
| EntrestoSacubitril/Valsartan | 18 | $20,993 |
| FarxigaDapagliflozin Propanediol | 20 | $14,029 |
| JardianceEmpagliflozin | 13 | $12,062 |
| Metoprolol Succinate | 42 | $481 |
| Bisoprolol Fumarate | 13 | $234 |
| Atorvastatin Calcium | 17 | $214 |
| Furosemide | 32 | $206 |
| Spironolactone | 21 | $77 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $60 |
| Carvedilol | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $144 | $20,99318 claims |
| AstraZenecaFarxiga | $125 | $14,02920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.